SLGL_OUT_1 [2025-04-17 12:37:09 -0400] 3854 Bytes | 1026 tokens | Cum: 1026 tkns (12.83% of 8k)
==========================================================================

Booyah, my friends! It's already 12:37:08 PM on Thu Apr 17, 2025 -0400, and I've got my eyes locked on Sol-Gel Technologies (SLGL), pushing up to 0.6309 from 0.4800. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Sol-Gel Technologies (SLGL)
IPO: 2018-02-01 (7 Years Ago)
Market Cap: $11,700,200
Shares Outstanding: 27,860,000
Exchange: XNAS
Description: Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.

Here’s a list of headlines for Sol-Gel Technologies:

Today 08:40AM - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.
Nov-20-24 12:00PM - SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
Nov-20-24 12:00PM 07:00AM - Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Nov-15-24 08:10AM - Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
Nov-15-24 08:10AM 07:00AM - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sep-17-24 09:55AM - SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aug-27-24 12:00PM - All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
Aug-17-24 11:27AM - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-08-16T11:00:00Z - Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
B2 - 2024-05-20T12:10:03Z - Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
B3 - 2024-05-20T11:00:00Z - Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
B4 - 2024-05-16T10:00:00Z - Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
B5 - 2024-05-14T21:15:03Z - Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
B6 - 2024-05-09T22:10:07Z - Sharecare, Inc. (SHCR) Reports Q1 Loss, Misses Revenue Estimates

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Sol-Gel Technologies (SLGL).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

SLGL_OUT_3 [2025-04-17 12:37:10 -0400] 968 Bytes | 255 tokens | Cum: 1283 tkns (16.04% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/16/2931464/0/en/Sol-Gel-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Updates.htmlSol-Gel Technologies reported financial results for Q2 2024, including a net income of $1.9 million. The company provided updates on its pipeline, including the ongoing Phase 3 trial for SGT-610 in Gorlin Syndrome and the proof-of-concept study for SGT-210 in Darier disease. Sol-Gel also announced licensing agreements for its approved products TWYNEO and EPSOLAY in Europe and South Africa.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_5 [2025-04-17 12:37:11 -0400] 980 Bytes | 321 tokens | Cum: 1606 tkns (20.08% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T12:40:29Z - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - Sol-Gel Technol...
A2 - 2025-04-17T12:58:37Z - Sol-Gel Technologies Ltd. (SLGL) sells U.S. rights for EPSOLAY and TWYNEO...
A3 - 2025-04-17T12:53:39Z - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. | Taiwan News | A...
A4 - 2025-04-17T12:44:31Z - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S....
A5 - 2025-04-17T12:53:38Z - Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S....

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SLGL_OUT_7 [2025-04-17 12:37:12 -0400] 1184 Bytes | 334 tokens | Cum: 1942 tkns (24.27% of 8k)
==========================================================================

Showing A1 (chunk 1 of 17): A1:
**Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. - Sol-Gel Technologies (NASDAQ:SLGL)**Date: 2025-04-17Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/g44862269/sol-gel-and-mayne-pharma-announce-the-purchase-of-epsolay-and-twyneo-in-the-u-sSol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial in Darier patients is ongoing;

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_9 [2025-04-17 12:37:13 -0400] 1182 Bytes | 302 tokens | Cum: 2246 tkns (28.07% of 8k)
==========================================================================

Showing A1 (chunk 2 of 17): 50% of the patients have already completed the trial

NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. SLGL, a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited MYX (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025, which is expected to extend the Company's cash runway into the first quarter of 2027. This agreement was executed following the mutual termination by Sol-Gel and Galderma of the exclusive five-year license agreement in the U.S. for both products.

EPSOLAY is a topical cream containing encapsulated benzoyl peroxide, 5%, for

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_11 [2025-04-17 12:37:14 -0400] 1182 Bytes | 283 tokens | Cum: 2531 tkns (31.64% of 8k)
==========================================================================

Showing A1 (chunk 3 of 17): the treatment of inflammatory lesions of rosacea (papulopustular rosacea) in adults. TWYNEO is a fixed-dose combination of encapsulated benzoyl peroxide, 3%, and encapsulated tretinoin, 0.1%, cream for the treatment of acne vulgaris.

Facilitating the amounts received from this agreement with Mayne Pharma, Sol-Gel will concentrate on the clinical and commercial development of its most advanced innovative product, SGT-610, a hedgehog signaling pathway blocker designed to potentially become the first ever preventative treatment of basal cell carcinomas (BCCs) in Gorlin syndrome patients, if approved.

Based on recent independent market research commissioned by Sol-Gel, in which the optimal price recommendation has been established, and based on prevalence of Gorlin syndrome in the U.S., Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 and $500 million annuall

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_13 [2025-04-17 12:37:15 -0400] 1182 Bytes | 294 tokens | Cum: 2827 tkns (35.34% of 8k)
==========================================================================

Showing A1 (chunk 4 of 17): y.

As of December 31, 2024, Sol-Gel had $19.5 million in cash, cash equivalents, and deposits and $4.4 million in marketable securities for a total balance of $23.9 million.

As of March 31, 2025, Sol-Gel had $16.9 million in cash, cash equivalents, and deposits and no marketable securities for a total balance of $16.9 million.

"We are pleased to enter into this agreement with Mayne Pharma," said Mori Arkin, Chairman of the Board and CEO of Sol-Gel. "Having concluded this U.S. transaction, we are in advanced stages of establishing the commercial network of Epsolay and Twyneo outside the U.S. Many partnership agreements have already been signed and others are under negotiation. If the forecasts of our partners, who all made upfront payments for the rights in their territories, are accurate, we believe that the value of the global business could far exceed that of the U.S. business alone

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_15 [2025-04-17 12:37:15 -0400] 1182 Bytes | 263 tokens | Cum: 3092 tkns (38.65% of 8k)
==========================================================================

Showing A1 (chunk 5 of 17): .

"This agreement with Mayne Pharma is expected to significantly enhance our cash position and enable us to bolster our SGT-610 program and bring the Phase-III trial to completion. In addition to the potential of SGT-610 in the U.S., we believe that the worldwide potential of SGT-610 is very significant as Gorlin syndrome is prevalent globally.

"Our Phase-III clinical trial is progressing well, with all of our 41 sites open for enrollment and approximately 80% of the planned number of patients enrolled. We confidentially expect to complete recruitment no later than the third quarter of this year and announce top-line results in the fourth quarter of 2026.

"With the funding of the clinical trial accomplished and the timeline established, we would like to share with our investors the reasons as to why we are optimistic about the trial's potential success."

Mr. Arkin further commented,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_17 [2025-04-17 12:37:16 -0400] 1182 Bytes | 264 tokens | Cum: 3358 tkns (41.98% of 8k)
==========================================================================

Showing A1 (chunk 6 of 17): "It is important to note that all the data supporting our optimistic outlook are based on our post-hoc analysis of the results of the Phase-III clinical study of patidegib that was conducted by our predecessor, PellePharm Inc.

"This type of analysis is called a 'post-hoc analysis', which we cannot assure you that its conclusions will be replicated in our study. With that said, I would like to explain the reasons for our optimism.

"The study conducted by PellePharm did not achieve the statistical significance of the primary endpoint. However, with the assistance of three independent statisticians and several clinical experts, all commissioned by Sol-Gel, significant findings were made after studying the data.

"Gorlin syndrome patients who lacked the PTCH-1 mutation responded poorly to patidegib.

"When we included in our analysis only patients with a confirmed hedgehog mutation and exc

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_19 [2025-04-17 12:37:17 -0400] 1182 Bytes | 276 tokens | Cum: 3636 tkns (45.45% of 8k)
==========================================================================

Showing A1 (chunk 7 of 17): luded an additional subset of patients, the superiority of patidegib became very significant - P <0.01. Our experts believe that this selection is not only warranted statistically but is based on sound scientific considerations."

Mr. Arkin further commented, "I am also pleased to share an update on Sol-Gel's of our vehicle controlled phase 1b clinical trial on SGT-210 (topical erlotinib) in patients with Darier disease, a significant unmet medical need with an estimated market potential of $200 to $300 million. If the trial will demonstrate the clinical efficacy that we expect, we anticipate filing for a Phase 2 IND in Q2 2025. SGT-210 is currently being used in a compassionate use treatment for a pediatric patient suffering from a rare disease, and the repeated requests for supply from the patient's family indicates to us that the drug was probably helpful for this patient."

About TWY

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_21 [2025-04-17 12:37:17 -0400] 1182 Bytes | 299 tokens | Cum: 3937 tkns (49.21% of 8k)
==========================================================================

Showing A1 (chunk 8 of 17): NEO and EPSOLAY

TWYNEO is a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, cream for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin. Tretinoin and benzoyl peroxide are widely prescribed separately for acne vulgaris; however, benzoyl peroxide causes degradation of the tretinoin molecule, thereby potentially reducing its effectiveness if used at the same time or combined in the same formulation. TWYNEO uses silica (silicon dioxide) core shell structures to separately micro-encapsulate tretinoin crystals and benzoyl peroxide crystals enabling inclusion of the two active ingredients in the cream.

EPSOLAY is a topical cream containing benzoyl peroxide (BPO), 5%, for the treatment of bumps and b

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_23 [2025-04-17 12:37:18 -0400] 1182 Bytes | 287 tokens | Cum: 4226 tkns (52.83% of 8k)
==========================================================================

Showing A1 (chunk 9 of 17): lemishes (inflammatory lesions) of rosacea in adults. EPSOLAY utilizes a proprietary, patented technology to encapsulate BPO within silica-based microcapsules to create a barrier between the medication and the skin. The silica-based shell is designed to slowly release BPO over time to provide a tolerable and effective treatment.

About Gorlin Syndrome and SGT-610

SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for prevention of BCCs in Gorlin syndrome patients, if approved. Gorlin syndrome, an autosomal dominant genetic disorder affecting approximately 1 in 27,000-31,000 people in the U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1) gene. Normally, the PTCH1 gene blocks the smoothened, frizzle class receptor (SMO) gene, turning off the hedgehog signaling pathway when it is not ne

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_25 [2025-04-17 12:37:20 -0400] 1183 Bytes | 290 tokens | Cum: 4518 tkns (56.47% of 8k)
==========================================================================

Showing A1 (chunk 10 of 17): eded. Mutations in the PTCH1 gene may cause a loss of PTCH1 function, release of SMO, and may allow BCC tumor cells to divide uncontrollably. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors.

About Darier Disease and SGT-210

SGT-210 is a topical erlotinib drug candidate that is formulated for the treatment of Darier Disease and other hyperkeratosis-related indications. Erlotinib is a tyrosine kinase receptor inhibitor that acts on the epidermal growth factor receptor, a protein present on cell surfaces that plays a key role in promoting cell growth and division. Darier Disease is a rare, genetic keratinization disorder which is classically characterized scaly crusted papules in a seborrheic distribution and in skin folds.

About Sol-Gel Technologies

Sol-Gel Technologies,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SLGL_OUT_27 [2025-04-17 12:37:20 -0400] 238 Bytes | 59 tokens | Cum: 4579 tkns (57.24% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SLGL_OUT_29 [2025-04-17 12:37:21 -0400] 251 Bytes | 78 tokens | Cum: 4660 tkns (58.25% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

SLGL_OUT_31 [2025-04-17 12:37:31 -0400] 5001 Bytes | 1191 tokens | Cum: 5854 tkns (73.17% of 8k)
==========================================================================

This is our set of metrics for Sol-Gel Technologies.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+------------------------+
| Volume: 1,405,164 | Perf Month: -6.80% | Option/Short: Yes / Yes | Sales Y/Y TTM: 603.12% |
+--------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 57.98K | Perf Quarter: -55.26% | Short Float: 0.14% | ROE: -24.59% |
+--------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 51.95 | Index: - | Short Ratio: 0.17 | ROI: -26.86% |
+--------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 53.88 | Market Cap: 15.12M | Short Interest: 0.01M | Sales Surprise: 27.64% |
+--------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.07 | Shs Outstand: 27.86M | Beta: 1.18 | EPS Surprise: 80.00% |
+--------------------+-----------------------+-------------------------+------------------------+
| SMA20: 9.74% | Shs Float: 7.23M | Sales Q/Q: 2416.90% | P/E: - |
+--------------------+-----------------------+-------------------------+------------------------+
| SMA50: -2.56% | Inst Own: 18.89% | Sales past 5Y: - | Earnings: Nov 15 BMO |
+--------------------+-----------------------+-------------------------+------------------------+
| SMA200: -16.79% | Insider Own: 74.04% | Employees: - | |
+--------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 32.41% | Insider Trans: 0.00% | Debt/Eq: 0.04 | |
+--------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by Sol-Gel Technologies officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.63
Average Volume: 169898.96
30-Day High: 0.63
30-Day Low: 0.41
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Sol-Gel Technologies (SLGL).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Sol-Gel Technologies.

2) MARKET_SCORE[]
This conversation was initiated because SLGL is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for SLGL.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, SLGL could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect SLGL to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Sol-Gel Technologies.

11) ETHICAL_RATING[]
Rate Sol-Gel Technologies’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Sol-Gel Technologies.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

SLGL_IN_33 [2025-04-17 12:37:32 -0400] 126 Bytes | 29 tokens | Cum: 6107 tkns (76.34% of 8k)
==========================================================================

====================================
[2025-04-17 12:37:32] # Analysis Completed
Elapsed Time: 23.03 seconds